Adaptimmune Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Adaptimmune Therapeutics yıllık ortalama 7.1% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.3% annual. Gelirler yılda ortalama 71.2% oranında büyüyor .
Anahtar bilgiler
7.1%
Kazanç büyüme oranı
19.6%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 71.2% |
| Özkaynak getirisi | -55.7% |
| Net Marj | -25.4% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Gelir ve Gider Dağılımı
Adaptimmune Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 175 | -45 | 70 | 0 |
| 30 Jun 24 | 141 | -72 | 79 | 0 |
| 31 Mar 24 | 18 | -163 | 77 | 0 |
| 31 Dec 23 | 60 | -114 | 72 | 0 |
| 30 Sep 23 | 71 | -95 | 68 | -105 |
| 30 Jun 23 | 71 | -91 | 61 | 0 |
| 31 Mar 23 | 71 | -114 | 59 | 0 |
| 31 Dec 22 | 27 | -165 | 61 | 0 |
| 30 Sep 22 | 18 | -175 | 63 | 105 |
| 30 Jun 22 | 12 | -176 | 61 | 0 |
| 31 Mar 22 | 9 | -171 | 60 | 0 |
| 31 Dec 21 | 6 | -158 | 57 | 0 |
| 30 Sep 21 | 6 | -156 | 56 | 0 |
| 30 Jun 21 | 6 | -149 | 54 | 0 |
| 31 Mar 21 | 4 | -140 | 50 | 0 |
| 31 Dec 20 | 4 | -130 | 46 | 0 |
| 30 Sep 20 | 3 | -123 | 43 | 0 |
| 30 Jun 20 | 2 | -127 | 41 | 0 |
| 31 Mar 20 | 2 | -138 | 41 | 0 |
| 31 Dec 19 | 1 | -137 | 43 | 0 |
| 30 Sep 19 | 2 | -144 | 43 | 0 |
| 30 Jun 19 | 42 | -99 | 43 | 0 |
| 31 Mar 19 | 51 | -102 | 44 | 0 |
| 31 Dec 18 | 60 | -96 | 44 | 0 |
| 30 Sep 18 | 62 | -87 | 42 | 0 |
| 30 Jun 18 | 49 | -93 | 39 | 0 |
| 31 Mar 18 | 43 | -69 | 36 | -19 |
| 31 Dec 17 | 38 | -70 | 31 | 0 |
| 30 Sep 17 | 42 | -58 | 29 | 17 |
| 30 Jun 17 | 17 | -76 | 26 | 32 |
| 31 Mar 17 | 14 | -78 | 24 | 68 |
| 31 Dec 16 | 14 | -72 | 23 | 0 |
| 30 Sep 16 | 10 | -73 | 23 | 63 |
| 30 Jun 16 | 12 | -61 | 21 | 57 |
| 31 Mar 16 | 15 | -55 | 21 | 48 |
| 31 Dec 15 | 14 | -48 | 18 | 40 |
| 30 Sep 15 | 13 | -19 | 14 | 29 |
| 30 Jun 15 | 10 | -37 | 10 | 24 |
| 31 Mar 15 | 7 | -16 | 8 | 19 |
| 31 Dec 14 | 4 | -12 | 5 | 16 |
| 30 Sep 14 | 2 | -13 | 4 | 14 |
| 30 Jun 14 | 1 | -12 | 3 | 10 |
Kaliteli Kazançlar: ADAP şu anda kârlı değil.
Büyüyen Kar Marjı: ADAP şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADAP kârlı değildir, ancak son 5 yılda zararlarını yılda 7.1% oranında azaltmıştır.
Büyüme Hızlandırma: ADAP 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: ADAP kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: ADAP hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -55.65% ) sahiptir.